Stallergenes Greer enters partnership to develop device and app

Stallergenes Greer and Aptar Pharma will collaborate to develop a new connected device with a companion app for patients going through treatment with the allergy company's allergen immunotherapy.

Photo: Joachim Adrian

The allergy company Stallergenes Greer has entered into a partnership with Aptar Pharma regarding the development of a novel connected device and a companion mobile app, the former reports in a press release.

The two new projects are meant for patients receiving allergen immunotherapy treatment, which can be administered under the tongue. According to the allergy company, the device and its app accessory will help keep track of patients' allergy treatment schedule to avoid premature discontinuation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs